Alector, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| ALEC | HALO | |
|---|---|---|
| Market Cap | $261.28 million | $11.96 billion |
| Revenue (TTM) | $13.86 million | $1.66 billion |
| Net Income (TTM) | $-117,854,000 | $413.60 million |
HALO leads on 3 of 3 size & scale factors.
Valuation
| ALEC | HALO | |
|---|---|---|
| P/E Ratio | — | 30.80 |
| Price / Book | -26.21 | 83.30 |
| Price / Sales | 18.85 | 7.19 |
ALEC and HALO split the valuation factors evenly.
Profitability
| ALEC | HALO | |
|---|---|---|
| Net Margin | -850.13% | 24.86% |
| Return on Equity | 1182.09% | 288.13% |
ALEC and HALO split the profitability factors evenly.
Risk & Sentiment
| ALEC | HALO | |
|---|---|---|
| Short Interest | 0.58% | 9.79% |
ALEC leads on 1 of 1 risk & sentiment factors.
Dig deeper: ALEC overview, ALEC financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.